IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2017

Conditions
Rectal Cancer
Interventions
DRUG

IXO regimen

"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."

Trial Locations (1)

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ottawa Regional Cancer Foundation

UNKNOWN

collaborator

Sanofi

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Ottawa Hospital Research Institute

OTHER